Clinical research of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma.
10.7534/j.issn.1009-2137.2013.02.038
- Author:
Zhi GUO
1
;
Hui-Ren CHEN
;
Xiao-Dong LIU
;
Jing-Xing LOU
;
Kai YANG
;
Yuan ZHANG
;
Peng CHEN
;
Shi-Yao WANG
;
Xue-Peng HE
Author Information
1. Department of Hematology, Beijing Military Area General Hospital, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Female;
Graft vs Host Disease;
prevention & control;
Hematopoietic Stem Cell Transplantation;
methods;
Humans;
Male;
Middle Aged;
Multiple Myeloma;
therapy;
Transplantation Conditioning;
methods;
Treatment Outcome
- From:
Journal of Experimental Hematology
2013;21(2):441-445
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to explore the efficacy and feasibility of reduced-intensity allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of multiple myeloma (MM). Three patients with MM from January 2011 to January 2012 in General Hospital of Beijing Military Area were treated by reduced-intensity allo-HSCT. All donors are compatriots and affinity HLA identical. Donors were mobilized with granulocyte colony-stimulating factor (G-CSF), the MM patients were given combined transplantation of bone marrow and peripheral blood stem cells. Preconditioning regimen consisted of fludarabine combined with melphalan and anti-human thymocyte globulin, and the classic cyclosporin A (CsA) combined with methotrexate (MTX) was used to prevent graft-versus-host disease (GVHD). The preventive donor peripheral blood stem cell infusion in dose 0.2×10(8)/kg mononuclear cells (MNC) was applied after 3 months of transplantation, then the toxicity, GVHD and disease-free survival (DFS) in patients were observed after transplantation. The results showed that 3 patients got hematopoietic reconstitution, the average time of neutrophils ≥ 0.5×10(9)/L and platelets ≥ 20×10(9)/L was 14.3 d and 15.3 d respectively, the detection of implanting efficacy displayed 100% complete donor hematopoiesis. Follow-up to January 2013, the median follow-up time was 13 months (12 to 15 months), As a result, none of the patients got GVHD, infection and other serious complications, all patients are still in complete remission (CR), the longest DFS time has reached to 15 months. It is concluded that the reduced-intensity allogeneic hematopoietic stem cell transplantation is the effective method for MM, this method has the high safety and efficacy, as well as high complete remission rate in early transplantation, the MM patients may get a long-term survival. This method can be used as a key technology in clinic for treating MM.
